Patent application number | Description | Published |
20080221505 | Expandable Blade Device for Stabilizing Compression Fractures - A medical device and method of using the device to reinforce and stabilize a compressed tissue is disclosed. The medical device is inserted into the tissue, typically a vertebral bone, cuts the tissue inside, and then a binding cement is injected into the pulped tissue without removing the tissue. The medical device is designed to disrupt and pulp the tissue without exerting a compressive force against the walls by using thin blades that buckle away from the core, and by rotating the blades while expanding/contracting the blades at the same time. | 09-11-2008 |
20080221575 | EXPANDABLE BLADE DEVICE FOR STABILIZING LONG BONE FRACTURES - The present invention relates generally to medical devices and medical methods, in particular, devices and methods useful for stabilizing fractures of long bones. In one embodiment, the present invention is a device comprising a housing having a lumen; a plunger having a proximal portion and a distal portion, where the plunger is disposed within the lumen and is movable relative to the housing; a plurality of blades, where the blades can expand radially from the axis of the housing; and a manipulator functionally connected to the plunger, wherein the manipulator is operable to: move the plunger relative to the housing; expand the blades radially from the axis of the housing; and move the blades about the axis of the plunger. | 09-11-2008 |
20080221608 | EXPANDABLE BLADE DEVICE FOR STABILIZING COMPRESSION FRACTURES - The present invention relates generally to medical devices and medical methods, in particular, devices and methods useful for stabilizing compression fractures of the spine. In one embodiment, the present invention is a device comprising a housing having a lumen; a plunger having a proximal portion and a distal portion, where the plunger is disposed within the lumen and is movable relative to the housing; a plurality of blades, where the blades can expand radially from the axis of the housing; and a manipulator functionally connected to the plunger, wherein the manipulator is operable to: move the plunger relative to the housing; expand the blades radially from the axis of the housing; and move the blades about the axis of the plunger. | 09-11-2008 |
20100249785 | Betts Osteotome - A medical device and method of using the device to reinforce and stabilize a compressed tissue is disclosed. The medical device comprises a shaft with a single blade that is biased with a bend, but is elastic enough to be straightened. The end of a cannula is inserted into a tissue, and the blade and shaft are then inserted into a cannula to straightens the blade and direct it to the tissue site. When the blade reaches the tissue site, the blade naturally returns to its bent biased state, and the shaft and blade are then rotated to pulp a volume of tissue. A binding material is then injected into the pulped tissue without removing the tissue. | 09-30-2010 |
20130030427 | Radiofrequency Catheter - An integrated catheter shaft with a guidewire and a radio frequency wire is used in a catheter to deliver radio frequency energy to a treatment site. The small entry wound and the long integrated catheter shaft allows a user to thread the shaft along a tortuous route along a spinal canal to reach a treatment site while causing a minimal amount of trauma to the patient. | 01-31-2013 |
Patent application number | Description | Published |
20140073528 | METHODS OF DEPLETING A TARGET MOLECULE IN A SAMPLE AND KITS FOR PRACTICING THE SAME - Provided are methods of depleting a target molecule in a sample. The methods include contacting a target molecule with a free radical-generating system and generating free radicals from the free radical-generating system to deplete the target molecule in the sample. Kits for practicing the subject methods are also provided. | 03-13-2014 |
20140113332 | TEMPLATE SWITCH-BASED METHODS FOR PRODUCING A PRODUCT NUCLEIC ACID - Provided are methods of producing a product nucleic acid. The methods include combining a template deoxyribonucleic acid (DNA), a polymerase, a template switch oligonucleotide, and dNTPs into a reaction mixture. The components are combined into the reaction mixture under conditions sufficient to produce a product nucleic acid that includes the template DNA and the template switch oligonucleotide each hybridized to adjacent regions of a single product nucleic acid that includes a region polymerized from the dNTPs by the polymerase. Aspects of the invention further include compositions and kits. | 04-24-2014 |
20150111789 | METHODS FOR ADDING ADAPTERS TO NUCLEIC ACIDS AND COMPOSITIONS FOR PRACTICING THE SAME - Provided are methods of adding adapters to nucleic acids. The methods include combining in a reaction mixture a template ribonucleic acid (RNA), a template switch oligonucleotide including a 3′ hybridization domain and a sequencing platform adapter construct, a polymerase, and dNTPs. The reaction mixture components are combined under conditions sufficient to produce a product nucleic acid that includes the template RNA and the template switch oligonucleotide each hybridized to adjacent regions of a single product nucleic acid that includes a region polymerized from the dNTPs by the polymerase. Aspects of the invention further include compositions and kits. | 04-23-2015 |
20150203906 | METHODS FOR ADDING ADAPTERS TO NUCLEIC ACIDS AND COMPOSITIONS FOR PRACTICING THE SAME - Provided are methods of adding adapters to nucleic acids. The methods include combining in a reaction mixture a template nucleic acid, a template switch oligonucleotide, a polymerase, and dNTPs. The reaction mixture components are combined under conditions sufficient to produce a product nucleic acid that includes the template nucleic acid and the template switch oligonucleotide each hybridized to adjacent regions of a single product nucleic acid including a region polymerized from the dNTPs by the polymerase. The methods further include attaching sequencing platform adapter constructs to ends of the product nucleic acid or a derivative thereof. Aspects of the invention further include compositions and kits. | 07-23-2015 |
20150225773 | METHODS OF DEPLETING A TARGET MOLECULE FROM AN INITIAL COLLECTION OF NUCLEIC ACIDS, AND COMPOSITIONS AND KITS FOR PRACTICING THE SAME - Provided are methods of depleting a target nucleic acid from an initial collection of nucleic acids. Aspects of the methods include contacting the initial collection with a nucleic acid guided nuclease specific for the target nucleic acid in a manner sufficient to deplete the target nucleic acid from the initial collection. Depending on a given application, depletion of a target nucleic acid may vary, e.g., where depleting may include cleaving a target nucleic acid in, or selectively separating a target nucleic acid from, the initial collection of nucleic acids. Also provided are compositions and kits for practicing embodiments of the methods. | 08-13-2015 |
Patent application number | Description | Published |
20080204041 | Differential Vector Network Analyzer - A measurement and correction method provides for a complete full correction of a true-mode system using only the single ended error matrix developed for 4 port correction of single ended measurements. The degree of misalignment of the balanced sources may be determined from these measurements. | 08-28-2008 |
20080258707 | Test Method for Frequency Converters with Embedded Local Oscillators - A method is presented where the phase trace is offset for each sweep such that the first point is always at zero degrees. The resulting traces are then averaged. The average reduces the noise in the phase trace and results in a less noisy group delay trace. | 10-23-2008 |
20090125264 | Nonlinear Measurement System Error Correction - A method for eliminating the systematic measurement errors from a measurement system, for example a vector network analyzer, such that an accurate representation of the behavior of a nonlinear device can be measured or characterized. The cross-frequency phase and absolute amplitude of the measured voltage waves applied to and emanating from the nonlinear device are measured and error corrected. These waves may be used for nonlinear device characterization or modeling. | 05-14-2009 |
20120243595 | METHOD AND SYSTEM FOR PROVIDING PHASE REFERENCE SIGNAL - A method and system of providing a phase reference signal includes generating a reference signal having a reference frequency, modulating the reference signal at a modulation frequency lower than the reference frequency to obtain a modulated drive signal, receiving the modulated drive signal at a phase reference, and generating the phase reference signal based on the modulated drive signal. The phase reference signal including multiple reference tones having corresponding tone frequencies clustered around multiples of the reference frequency. A spacing between adjacent tones of the multiple reference tones is the same as the modulation frequency or an integer multiple of the modulation frequency. | 09-27-2012 |
20150369849 | DETERMINING OPERATING CHARACTERISTICS OF SIGNAL GENERATOR USING MEASURING DEVICE - A method determines operating characteristics of a signal generator. The method includes performing a first set of measurements of an output signal generated by the signal generator and corresponding reflected signal, where the first set of measurements is performed over multiple frequencies and amplitudes of the output signal; applying an external signal to the output port of the signal generator; performing a second set of measurements of the output signal and corresponding reflected signal while the external signal is being applied to the output port, where the second set of measurements is performed over frequencies and amplitudes of the output signal, the external signal having the same frequency as the output signal for each measurement of the second set of measurements. A set of coefficients describing the operating characteristics of the signal generator is determined by processing results of the first and second sets of measurements through a non-linear model. | 12-24-2015 |
Patent application number | Description | Published |
20100055145 | STENT COATINGS FOR REDUCING LATE STENT THROMBOSIS - Devices and methods relate to drug-eluting stents and coatings, thereof, for reduced late stent thrombosis are described. | 03-04-2010 |
20100094408 | Drug-Delivery Endovascular Stent and Method for Treating Restenosis - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns. | 04-15-2010 |
20110123704 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD FOR TREATING RESTENOSIS - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating. | 05-26-2011 |
20120029626 | DRUG DELIVERY ENDOVASCULAR STENT AND METHOD OF USE - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments where at least one surface of the filaments has a roughened or abraded surface. The stent may include a therapeutic agent on the abraded surface. | 02-02-2012 |
20120290076 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD FOR TREATING RESTENOSIS - A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments and a liquid-infusible mechanical anchoring layer attached to or formed in outer surface of the filaments. A drug coating in the stent is composed of a substantially polymer-free composition of an anti-restenosis drug, and has a substratum infused in the anchoring layer and a substantially continuous surface stratum of drug that is brought into direct contact with the vessel walls at the vascular site. Thus, the rate of release of the anti-restenosis drug from the surface stratum into said vascular site is determined solely by the composition of said drug coating. | 11-15-2012 |
20120330406 | DRUG DELIVERY ENDOVASCULAR STENT AND METHOD OF USE - An improvement in drug-eluting stents, and method of their making, are disclosed. The surface of a metal stent is roughened to have a surface roughness of at least about 20 μin (0.5 μm) and a surface roughness range of between about 300-700 μin (7.5-17.5 μm). The roughened stent surface is covered with a polymer-free coating of a limus drug, to a coating thickness greater than the range of surface roughness of the roughened stent surface. | 12-27-2012 |
20130006350 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD FOR TREATING RESTENOSIS - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns. | 01-03-2013 |
20130035754 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD OF FORMING THE SAME - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-Iactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns. | 02-07-2013 |
20140200654 | DRUG-DELIVERY ENDOVASCULAR STENT AND METHOD OF FORMING THE SAME - An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns. | 07-17-2014 |
20150297662 | RAPAMYCIN 40-O-CYCLIC HYDROCARBON ESTERS, COMPOSITIONS AND METHODS - A new class of rapamycin 40-O-cyclic hydrocarbon esters is disclosed. The 40-O position of the rapamycin ester has the form 40-O—R, where R is C(O)—(CH | 10-22-2015 |